Relievant Medsystems, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Relievant Medsystems, Inc. - overview

Established

2006

Location

Edina, MN, US

Primary Industry

Medical Devices & Equipment

About

Relievant Medsystems, Inc. is a US-based medical technology company focused on providing innovative treatments for vertebrogenic low back pain through its minimally invasive Intracept Procedure. Founded in 2006 in Edina, US, Relievant Medsystems, Inc. specializes in addressing chronic low back pain with its Intracept Procedure.


The CEO, Art Taylor, leads the company following its recent acquisition by Boston Scientific Corporation on September 19, 2023, for USD 850. 00 mn, allowing Boston Scientific to enhance its chronic pain portfolio. Relievant has completed a total of 11 deals, demonstrating significant business activity since its inception. Relievant's primary offering is the Intracept Procedure, a minimally invasive treatment for patients suffering from vertebrogenic low back pain.


This procedure employs targeted radiofrequency energy to disrupt pain signaling, addressing the root causes of the condition. Supported by three clinical trials, it has shown substantial improvements in pain levels for chronic low back pain patients. The company serves a diverse client base, including healthcare providers in pain management, orthopedics, and neurology across North America, Europe, and select Asian markets. Relievant generates revenue through the Intracept Procedure, collaborating with healthcare facilities and practitioners.


The company’s revenue model involves direct transactions with hospitals, which bill insurers for the procedure, ensuring patient access. Pricing varies by region and facility, reflecting operational costs and reimbursement rates, with the Intracept Procedure positioned as a primary solution for chronic low back pain management. Following the acquisition finalized on September 19, 2023, Relievant Medsystems, Inc. plans to leverage its new partnership with Boston Scientific Corporation to further integrate the Intracept system into broader pain management strategies.


The acquisition funding of USD 850. 00 mn will support development initiatives and market expansion efforts, allowing Relievant to enhance its offerings and reach new geographic markets.


Current Investors

Morgenthaler Ventures, New Enterprise Associates, Canaan Partners

Primary Industry

Medical Devices & Equipment

Sub Industries

Medical Devices & Equipment, Search Engines

Website

www.relievant.com

Company Stage

Acquired

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.